Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Inventory (2022 - 2025)

Historic Inventory for Gyre Therapeutics (GYRE) over the last 5 years, with Q3 2025 value amounting to $8.9 million.

  • Gyre Therapeutics' Inventory rose 3879.92% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 3879.92%. This contributed to the annual value of $6.3 million for FY2024, which is 4802.62% up from last year.
  • Gyre Therapeutics' Inventory amounted to $8.9 million in Q3 2025, which was up 3879.92% from $8.9 million recorded in Q2 2025.
  • Gyre Therapeutics' Inventory's 5-year high stood at $8.9 million during Q2 2025, with a 5-year trough of $4.3 million in Q4 2023.
  • Over the past 4 years, Gyre Therapeutics' median Inventory value was $6.3 million (recorded in 2024), while the average stood at $6.6 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Inventory plummeted by 3007.19% in 2023, and later soared by 5950.6% in 2025.
  • Gyre Therapeutics' Inventory (Quarter) stood at $6.1 million in 2022, then tumbled by 30.07% to $4.3 million in 2023, then soared by 48.03% to $6.3 million in 2024, then surged by 39.72% to $8.9 million in 2025.
  • Its last three reported values are $8.9 million in Q3 2025, $8.9 million for Q2 2025, and $7.9 million during Q1 2025.